Most Recent Articles about AGN
Satsuma Plunges on Disappointing Data on Migraine Treatment http://www.zacks.com/stock/news/1057087/satsuma-plunges-on-disappointing-data-on-migraine-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1057087 Sep 11, 2020 - Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs http://www.zacks.com/stock/news/883666/roche-rhhby-q1-sales-grow-on-solid-performance-of-new-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-883666 Apr 22, 2020 - Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.
How Safe Are AbbVie Stock and Its Dividend? https://www.fool.com/investing/2020/04/16/how-safe-is-abbvie-stock-and-its-dividend.aspx?source=iedfolrf0000001 Apr 16, 2020 - Is it possible to have both growth and safety in this market?

Related Companies

Name Exchange Price Mkt Cap
CELG Celgene Corporation NASDAQ $87.23 $61.35B
SHPG Shire plc NASDAQ $176.25 $46.08B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $175.8 $44.93B
ZTS Zoetis Inc. NYSE $88.3 $42.55B
REGN Regeneron Pharmaceuticals, Inc. NASDAQ $386.665 $41.78B
Sector: Health Care > Industry: Major Pharmaceuticals